在多剂化疗中加入JNK独立药物可以改善复发性高危神经母细胞瘤的反应
Jeremy Z R Han1, Monica Phimmachanh1, Jordan F Hastings1
1Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
Science advances
|November 28, 2025
概括
化学抵抗性神经母细胞瘤可以通过向c-Jun氨基终端激酶 (JNK) 独立的亡途径来克服. 新的药物组合可以提高癌症复发的治疗效率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 化学抵抗显著恶化了神经母细胞瘤的预后.
- 在c-Jun氨基终端激酶 (JNK) 信号传导中的异质性驱动神经母细胞瘤中的非遗传化学抵抗.
- 在复发性神经母细胞瘤中,JNK通路损伤是有效化疗的主要障碍.
研究的目的:
- 为了确定诱导化学抵抗性神经母细胞瘤中亡的JNK独立药物.
- 研究新型JNK独立药物与标准化疗之间的协同机制.
- 在复发性神经母细胞瘤的临床前模型中评估组合疗法的疗效.
主要方法:
- 开发了JNK激活的数学模型.
- 进行了以儿科为重点的药物选,以确定JNK独立的亡诱导物.
- 利用功能性基因组学来阐明协同作用机制.
- 在患者衍生异种移植模型中测试药物疗效.
主要成果:
- 识别了已批准的致癌药物,可独立于JNK诱导细胞亡.
- 发现协同效应源于差异性亡网络组件的利用,而不是直接的目标参与.
- 在复发性神经母细胞瘤模型中,使用结合的JNK独立和标准化疗,证明了治疗反应的显著改善.
结论:
- 独立于JNK的药物为克服神经母细胞瘤化学抵抗提供了一个有希望的策略.
- 针对JNK独立途径的组合疗法在复发情况下提高了疗效.
- 新的治疗方法对于改善复发性神经母细胞瘤的结果至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
524
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
524
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
790
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
790
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


